Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Phase 2

Conditions: Breast Cancer

First Posted Date: 2006-11-10

Last Posted Date: 2010-11-09

Lead Sponsor: Technical University of Munich

Target Recruit Count: 94

Registration Number: NCT00398489

Locations: 🇩🇪
Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany
🇩🇪
Klinikum Deggendorf, Deggendorf, Germany
🇩🇪
Universitaetsfrauenklinik - Koeln, Cologne, Germany

and more 2 locations

Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma

Phase 3

Completed

Conditions: Advanced HCC

First Posted Date: 2006-11-07

Last Posted Date: 2009-02-04

Lead Sponsor: Hannover Medical School

Target Recruit Count: 12

Registration Number: NCT00396682

Locations: 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

Phase 3

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: carboplatin
Drug: temozolomide
Drug: cisplatin
Drug: thiotepa
Drug: cyclophosphamide
Drug: vincristine sulfate
Drug: etoposide
Procedure: autologous bone marrow transplantation
Drug: methotrexate
Procedure: autologous hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2006-10-26

Last Posted Date: 2013-12-18

Lead Sponsor: Children's Hospital Los Angeles

Target Recruit Count: 120

Registration Number: NCT00392886

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇦🇺
Princess Margaret Hospital for Children, Perth, Western Australia, Australia
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 34 locations

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Phase 3

Active, not recruiting

Conditions: Anaplastic Medulloblastoma
Medulloblastoma

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Procedure: Lumbar Puncture
Biological: Filgrastim
Drug: Isotretinoin
Procedure: Magnetic Resonance Imaging
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Drug: Vincristine Sulfate

First Posted Date: 2006-10-26

Last Posted Date: 2024-01-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 379

Registration Number: NCT00392327

Locations: 🇺🇸
Inova Fairfax Hospital, Falls Church, Virginia, United States
🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States
🇵🇷
University Pediatric Hospital, San Juan, Puerto Rico

and more 182 locations

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: doxorubicin hydrochloride
Drug: ifosfamide
Drug: liposomal cytarabine
Drug: leucovorin calcium
Drug: methotrexate
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate

First Posted Date: 2006-10-26

Last Posted Date: 2018-06-06

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 34

Registration Number: NCT00392834

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸
Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, Washington, United States

and more 10 locations

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

Phase 2

Completed

Conditions: Anti-p53 TCR-Gene

Interventions: Biological: anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes
Biological: aldesleukin
Biological: filgrastim
Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2006-10-26

Last Posted Date: 2011-08-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00393029

Locations: 🇺🇸
National Institutes of Health, Bethesda, Maryland, United States

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Phase 2

Completed

Conditions: BCR-ABL1 Fusion Protein Expression
Recurrent Acute Lymphoblastic Leukemia
t(9;22)
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive
Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dasatinib
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Methotrexate
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2006-10-20

Last Posted Date: 2024-02-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 107

Registration Number: NCT00390793

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Biological: rituximab
Biological: sargramostim
Drug: cyclophosphamide
Drug: pegylated liposomal doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

First Posted Date: 2006-10-19

Last Posted Date: 2018-06-06

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 43

Registration Number: NCT00389818

Locations: 🇺🇸
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸
Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States

and more 11 locations